Lung oncologist, tumor immunology & KRAS researcher, advocate for lung cancer patients and learners @pmcancercentre, @uoftmedicine, @UofT. He/Him/Il. π³οΈβπ
Joined October 2015
- Tweets 490
- Following 1,442
- Followers 1,012
- Likes 3,112
3 Photos and videos
Pinned Tweet
24 Aug 2023
Setting the bar higher for KRAS inhibitors - pleased to share our study of divarasib in KRAS G12C lung/colon/solid tumors in @NEJM. Impressive response rate, durability and tolerability. Thanks to pts and co-investigators. @KRASKickers #lcsm
Among patients with cancers bearing the KRAS G12C mutation who received divarasib at a 400-mg dose, 56% with lung cancer, 36% with colorectal cancer, and 36% with other tumor types had a confirmed response.
π Read the full study results: nej.md/45xZYok
#oncology
5
9
60
7,229
Adrian Sacher, M.D. retweeted
π¨ Check our Top 10 #LungCancer abstracts for ELCC 2026!
We've hand-picked the must-see sessions with times & presenters.
ποΈ Stay on track in Copenhagen and simply import these directly to your calendar by clicking this link:
lungsummit.org/elcc2026.ics
Which lung abstracts are your favorites at ELCC26 #LCSM @IASLC @myESMO
ALT π¬ Our picks: 1οΈβ£ LBA1 β LATIFY: Ceralasertib durvalumab post-IO NSCLC β B. Besse 2οΈβ£ LBA2 β i-TIMES: Timing of immunotherapy β first results β S. Peters 3οΈβ£ LBA3 β NorthStar: Local consolidative RT in EGFRm NSCLC β S. Gandhi 4οΈβ£ LBA4 β OptiTROP-Lung03: Sac-TMT final OS in EGFRm NSCLC β Y. Yang 5οΈβ£ LBA5 β One-time low dose CT screening & lung cancer mortality β C. Li 6οΈβ£ 1O β Setidegrasib in KRAS G12D-mutant NSCLC β L. Paz-Ares 7οΈβ£ 2O β TOP study: Osimertinib Β± chemo in TP53-mutant EGFRm NSCLC β Y. Yang 8οΈβ£ 3O β PRESERVE-003: Gotistobart vs docetaxel in sqNSCLC β K. He 9οΈβ£ 4MO β KANDLELIT-001: MK-1084 pembro in KRAS G12C β A. Sacher π 5MO β ADEPPT: Adagrasib in elderly/poor PS KRASG12C NSCLC β J. Naidoo
1
31
74
6,927
Adrian Sacher, M.D. retweeted
28 Aug 2025
π£ Updated ESMO #ClinicalPracticeGuideline on early & locally advanced #NSCLC: new systemic treatments, innovative strategies & advanced therapeutic options to personalise #PatientCare & improve outcomes.
π ow.ly/yU4i50WM0Uk
#LungCancer #SystemicTherapy #Oncology #CancerTreatment
1
26
61
11,468
Adrian Sacher, M.D. retweeted
22 Aug 2025
ποΈ New #LungCancerVoices Podcast episode! @pwheatleyprice & @DocSacher talk about all there is to know about #KRAS lung cancer. What is KRAS, how it's tested, what it means in terms of treatment options for those who have this subtype.
βΆοΈ Listen now at bit.ly/LCCPodcast
1
3
8
274
Adrian Sacher, M.D. retweeted
5 May 2025
Early phase trials: the perils of nonpublication
@DocSacher @susanebates
doi.org/10.1093/oncolo/oyaf0β¦
3
4
582
Adrian Sacher, M.D. retweeted
16 Sep 2024
#ESMO24 concomitant paper: @DocSacher presents the First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor at today's Presidential Symposium @HPrenen
4
9
1,449
Adrian Sacher, M.D. retweeted
16 Sep 2024
AMG 193 Shows Preliminary Clinical Activity in MTAP-Deleted Solid Tumors @DocSacher @pmcancercentre @uoftmedicine @UofT #ESMO24 #ESMO2024 #MedTwitter onclive.com/view/amg-193-shoβ¦
2
4
938
Adrian Sacher, M.D. retweeted
1 Jun 2024
Excellent summary of #KRASG12C trials in the metastatic NSCLC space by @DocSacher @ASCO #ASCO24
β¨ 2L tx TKI v. Docetaxel
β¨ combination TKI IO
β¨ combination with chemo
β¨ combination with EGFR
Lot if interest in this space and congrats to all the authors @OncoAlert
26
67
11,136
Adrian Sacher, M.D. retweeted
24 May 2024
Excited for #ASCO24! While disease specific content is best found in oral session dedicated to a disease group, explore thematic Clinical Science Symposia that are a highlight - such as the special session on #KRAS In #NSCLC
πHall B1, Sat, Jun 1 @TonyMok9 @DocSacher @KCArbourMD
3
7
1,221
Adrian Sacher, M.D. retweeted
24 Apr 2024
Not one, not 2, but 3 lung cancer plenaries at #ASCO24 ! Early telemed pall care, the LAURA trial of consolidation osimertinib after CRT for stage 3 EGFR non small cell lung cancer & the ADRIATIC trial of consolidation immunotherapy after CRT for small cell lung cancer! #lcsm
#ASCO24 garnered a record number of abstract submissions!
Preview the abstract titles to see what will be presented or published at this yearβs meeting and browse the meeting program to start planning your schedule β‘οΈ brnw.ch/21wJ8kD
4
28
112
15,814
Adrian Sacher, M.D. retweeted
22 Feb 2024
Next up #TTLC24 Targeted Therapies: KRAS, BRAF, SHP2, SOS1 kicks off w/ @FSkoulidis @Dobeze_ @DrMarkAwad @AlexSpiraMDPhD @SukiPadda @kamarroneMD @NaglaAKarimMD @DocSacher @NIVokes!
4
7
992
Adrian Sacher, M.D. retweeted
5 Oct 2023
Pleased to participate in #Coalition4CdnResearch press conference with all Canadian advocacy groups coming together to call on the federal government to invest in research. @cafreeland @KirstyDuncanMP @JustinTrudeau
5 Oct 2023
"It's past time for the government to make a major investment in Canadian research." - Dr. Brad Wouters, Executive VP Science & Research at @UHN, representing @HealthCareCAN, and a Research Canada Board Director
Read #Coalition4CdnResearch's open letter: ow.ly/yXg450PTuPI
4
36
173
27,276
Adrian Sacher, M.D. retweeted
29 Aug 2023
Exciting new clinical findings from @DocSacher @pmcancercentre @UHN_Research demonstrating potential of targeting KRAS
29 Aug 2023
Dr. Adrian Sacher (@DocSacher) @UHN co-led a multi-national effort to test a new anticancer drug in patients with non-small-cell lung cancer and colon cancer. With few serious side effects found, further testing is warranted. > uhnresearch.ca/news/advancinβ¦; doi.org/10.1056/NEJMoa230381β¦
ALT Image of smiling male researcher in business casual.
1
15
2,320
Adrian Sacher, M.D. retweeted
1 Aug 2023
π Dr. @DocSacher's research uncovers potential treatments for lung cancer patients facing drug resistance. With LCFA backing, he takes crucial steps towards a brighter future for those battling lung cancer. #Livingwithlungcancer #WLCD23 #lungcancer bit.ly/44Czi5C
1
5
419
Adrian Sacher, M.D. retweeted
1 Aug 2023
π¬ Dr. @DocSacher's mission is to comprehend the body's immune response to cancer cells. With LCFA's support, he explores novel therapies that may transform treatment approaches. π± #Livingwithlungcancer #LCFAmerica #LCFAResearch #WLCD23 #lungcancer bit.ly/44Czi5C
1
5
356
3 Aug 2023
The support of @lcfamerica and patients & their families has been essential to our ongoing work to end lung cancer. Thank you so much - great things to come!
1 Aug 2023
π As a Clinical Investigator and Assistant Professor, Dr. @DocSacher's impact on lung cancer research is undeniable. His dedication to immunotherapy brings hope to patients worldwide. π #Livingwithlungcancer #LCFAResearch #WLCD23 #lungcancer bit.ly/44Czi5C
1
2
19
1,862
Canadian Consensus Recommendations on the Management of KRASm G12C #NSCLC #KRAS π«
π»
doi.org/10.3390/curroncol300β¦
8
31
3,943
Adrian Sacher, M.D. retweeted
22 Apr 2023
Upfront Atezolizumab Poses Lower Risk of Hyperprogression in NSCLC cancertherapyadvisor.com/homβ¦
1
2
4
622
19 Apr 2023
Really amazing data on GDC-6036 plus cetuximab in KRAS G12C metastatic colon cancer - ORR 62% !!! More potent KRAS G12C inhibitors make for more effective combos & better options for patients. #AACR23 @KRASKickers
1
11
61
7,926